AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1

Javaglip-MS 50/500 Tablet

Prescription Icon
Prescription Required

Marketer

Adi Healthcare

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Javaglip-MS 50/500 Tablet

Metformin/glimepiride 50/500 mg tablets manage elevated blood glucose in type 2 diabetes patients by combining two active ingredients. This dual action helps mitigate serious diabetic complications like renal impairment and vision loss, potentially lessening heart attack and stroke risk. This medication might be prescribed solely or alongside other antidiabetic agents. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is tailored to individual health status, blood sugar readings, and concurrent medications. Consuming it with meals minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes efficacy; discontinuation should only occur under physician guidance. Adherence to the prescribed diet and exercise plan is crucial for effective diabetes management, as lifestyle significantly influences blood sugar control. Common side effects include nausea, vomiting, diarrhea, stomach upset, headache, and pharyngitis. Hypoglycemia is a potential adverse effect, especially when used with insulin or sulfonylureas; understanding hypoglycemia recognition and treatment is vital. This medication isn't universally suitable. Individuals with prior kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption should inform their doctor before commencing treatment. Pregnant or lactating individuals should seek medical advice. Interactions with other medications are possible; comprehensive disclosure of all medications to your physician is essential for safety. Alcohol should be limited due to its potential to lower blood glucose. Kidney function and blood sugar levels are monitored regularly throughout treatment.

Primary Ingredients of Javaglip-MS 50/500 Tablet

No information provided. Please provide the text you wish to be rephrased.

Uses of Javaglip-MS 50/500 Tablet

Managing type 2 diabetes

Major Benefits of Javaglip-MS 50/500 Tablet:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Javaglip-MS 50/500 Tablet whole; avoid crushing, chewing, or breaking it. Administer this medication with a meal.

Common Side effects of Javaglip-MS 50/500 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Javaglip-MS 50/500 Tablet:

Consume this medication precisely as prescribed by your physician, adhering to the recommended dosage and treatment period. Ingest the Javaglip-MS 50/500 Tablet whole; avoid chewing, crushing, or fracturing it. It should be taken with a meal.

How Javaglip-MS 50/500 Tablet works:

The dual-action tablet, Javaglip-MS 50/500, combines sitagliptin and metformin to manage blood glucose. Sitagliptin boosts insulin production from the pancreas, enhances insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and improves insulin responsiveness. This synergistic effect leads to improved glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Javaglip-MS 50/500 Tablet with alcohol is not advisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Javaglip-MS 50/500 tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible dangers prior to prescribing this medication. Seek medical advice before use.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Using Javaglip-MS 50/500 tablets while breastfeeding is likely inadvisable. Preliminary human evidence indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood sugar levels. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Javaglip-MS 50/500 Tablets cautiously, potentially requiring dosage modification. Physician consultation is essential. Javaglip-MS 50/500 Tablets are contraindicated in those with severe kidney disease. Routine monitoring of renal function is recommended during treatment.

LiverLiverUNSAFE

The use of Javaglip-MS 50/500 tablets is likely inadvisable for individuals with hepatic impairment and should be forgone. Medical advice is recommended.

What if you forget to take Javaglip-MS 50/500 Tablet :

Should you forget a Javaglip-MS 50/500 Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Javaglip-MS 50/500 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Javaglip-MS 50/500 Tablet

Javaglip-MS 50/500 tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged Javaglip-MS 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), and urinary or cognitive issues. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Javaglip-MS 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Patients with known allergies to Javaglip-MS 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis should not use this medication.
Combining Javaglip-MS 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication. Keep it out of reach of children, pets, and others.
Metformin, a component of Javaglip-MS 50/500 Tablet, can cause lactic acidosis (MALA—Metformin-associated lactic acidosis), a serious medical emergency resulting from excessive blood lactic acid. This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If experienced, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Javaglip-MS 50/500 tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. It's not suitable for individuals under 18.
Javaglip-MS 50/500 Tablet may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Javaglip-MS 50/500 Tablets are contraindicated in patients with known allergies to any ingredient or excipient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Javaglip-MS 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Lactic acidosis, a serious medical emergency (also known as MALA—Metformin-associated lactic acidosis), is a possible side effect of Javaglip-MS 50/500 Tablet. This is due to a buildup of lactic acid in the blood and is rare, but avoided in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms can include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Prolonged Javaglip-MS 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Javaglip-MS 50/500 tablets combine sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Javaglip-MS 50/500 Tablets may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Patients with known allergies to Javaglip-MS 50/500 Tablet components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Combining Javaglip-MS 50/500 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Taking Javaglip-MS 50/500 Tablets can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect necessitates caution in patients with kidney disease, older adults, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin + Metformin and seek immediate medical attention.
Prolonged Javaglip-MS 50/500 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Javaglip-MS 50/500 Tablet
373